Revium Recovery Inc.

RVRC: 10-Q · periodic report

Revium Rx. filed its Q2 2026 10-Q with a going-concern warning: the preclinical biopharmaceutical company held roughly $1.5 million in cash and short-term deposits at June 30, 2026 against a $26.4 million accumulated deficit, with no revenue, no binding commitments for further investment, and management stating there is substantial doubt about its ability to continue as a going concern. Quarterly results improved modestly. Q2 net loss fell 28% year-over-year to $748 thousand as G&A was cut 47% to $289 thousand, while R&D rose 13% to $443 thousand as the Nano-Mupirocin program advanced toward the clinic, with Israeli Ministry of Health approval to begin Phase 1 trials in healthy volunteers received February 18, 2026. Setbacks mounted elsewhere: the Nano-Candesartan program is on hold amid a dispute with Yissum over an expired option period, LPLT vaccine study results remain delayed, and the Israel Innovation Authority rejected a non-dilutive funding application on May 28, 2026. Management also concluded the company's disclosure controls and procedures are not effective. Leadership churned during the quarter: Igor Bluvstein was appointed CFO on May 27, 2026, replacing Arie Gordashnikov, and Inna Martin resigned as COO, President and director on June 10, 2026, triggering $45 thousand in termination benefits and a $111 thousand charge to extend her 2,440,000 vested options to September 30, 2028.

SEC 10-Q•2mo ago

RVRC: 8-K · leadership change

Ms. Inna Martin resigned from her positions as Director, Chief Operating Officer, and President of Revium Rx. effective immediately on June 16, 2026. The resignation was attributed to differences in expectations between Ms. Martin and the Company. Pursuant to a Separation Agreement, Ms. Martin's employment and consultancy engagement with the Company's subsidiary will terminate on September 10, 2026. The agreement also extends the exercise period for her 2,440,000 vested stock options to purchase common stock until September 30, 2028. The departure represents a significant change in the company's senior leadership structure.

SEC 8-K•4mo ago

RVRC: 10-Q · periodic report

Revium Rx reported a net loss of $725,000 for the first quarter of 2026, driven by $473,000 in R&D expenses and $266,000 in G&A costs, leaving the company with approximately $2.1 million in cash and short-term deposits. The filing includes a critical going-concern warning, stating that substantial doubt exists about the company’s ability to continue as a going concern due to its accumulated deficit of $25.7 million and lack of binding commitments for further investment. Additionally, management disclosed that internal disclosure controls and procedures are not effective, citing weaknesses in recording and reporting information required for SEC filings, which raises significant governance and compliance risks for investors.

SEC 10-Q•5mo ago